Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2020 1
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. Among authors: perez l. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. J Clin Oncol. 2021. PMID: 34170745 Free PMC article. Clinical Trial.
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, Myskowski P, Vardhana S, Ganesan N, Hancock H, Davey T, Perez L, Ryu S, Santarosa A, Dowd J, Obadi O, Pomerantz L, Yi N, Sohail S, Galasso N, Neuman R, Liotta B, Blouin W, Baik J, Geyer MB, Noy A, Straus D, Kumar P, Dogan A, Hollmann T, Drill E, Rademaker J, Schoder H, Inghirami G, Weinstock DM, Horwitz SM. Moskowitz AJ, et al. Among authors: perez l. Blood. 2021 Dec 30;138(26):2828-2837. doi: 10.1182/blood.2021013379. Blood. 2021. PMID: 34653242 Free PMC article. Clinical Trial.
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial.
Sosa S, Bringas G, Urrutia N, Peñalver AI, López D, González E, Fernández A, Hernández ZM, Viña A, Peña Y, Batista JF, Valenzuela C, León K, Crombet T, Rodríguez T, Pérez L; ATHENEA Investigators. Sosa S, et al. Among authors: perez l. Alzheimers Res Ther. 2023 Dec 13;15(1):215. doi: 10.1186/s13195-023-01356-w. Alzheimers Res Ther. 2023. PMID: 38093366 Free PMC article. Clinical Trial.
Amazon tree dominance across forest strata.
Draper FC, Costa FRC, Arellano G, Phillips OL, Duque A, Macía MJ, Ter Steege H, Asner GP, Berenguer E, Schietti J, Socolar JB, de Souza FC, Dexter KG, Jørgensen PM, Tello JS, Magnusson WE, Baker TR, Castilho CV, Monteagudo-Mendoza A, Fine PVA, Ruokolainen K, Coronado ENH, Aymard G, Dávila N, Sáenz MS, Paredes MAR, Engel J, Fortunel C, Paine CET, Goret JY, Dourdain A, Petronelli P, Allie E, Andino JEG, Brienen RJW, Pérez LC, Manzatto ÂG, Zambrana NYP, Molino JF, Sabatier D, Chave J, Fauset S, Villacorta RG, Réjou-Méchain M, Berry PE, Melgaço K, Feldpausch TR, Sandoval EV, Martinez RV, Mesones I, Junqueira AB, Roucoux KH, de Toledo JJ, Andrade AC, Camargo JL, Del Aguila Pasquel J, Santana FD, Laurance WF, Laurance SG, Lovejoy TE, Comiskey JA, Galbraith DR, Kalamandeen M, Aguilar GEN, Arenas JV, Guerra CAA, Flores M, Llampazo GF, Montenegro LAT, Gomez RZ, Pansonato MP, Moscoso VC, Vleminckx J, Barrantes OJV, Duivenvoorden JF, de Sousa SA, Arroyo L, Perdiz RO, Cravo JS, Marimon BS, Junior BHM, Carvalho FA, Damasco G, Disney M, Vital MS, Diaz PRS, Vicentini A, Nascimento H, Higuchi N, Van Andel T, Malhi Y, Ribeiro SC, Terborgh JW, Thomas RS, Dallmeier F, Prieto A, Hilário RR, Sa… See abstract for full author list ➔ Draper FC, et al. Among authors: perez lc. Nat Ecol Evol. 2021 Jun;5(6):757-767. doi: 10.1038/s41559-021-01418-y. Epub 2021 Apr 1. Nat Ecol Evol. 2021. PMID: 33795854 Free article.
Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario.
Diaz H, Jiménez J, Hernández A, Valdés L, Martínez A, Porto L, Hernández R, Travieso N, Jova JH, Medel L, Troche M, Gorte A, Batista D, Valls AR, Cabrera L, Domeq M, Pérez L, Lorenzo-Luaces P, Sánchez L, Saavedra D, Ramos M, Crombet T. Diaz H, et al. Among authors: perez l. Front Public Health. 2022 Jul 22;10:948520. doi: 10.3389/fpubh.2022.948520. eCollection 2022. Front Public Health. 2022. PMID: 35937253 Free PMC article.
Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator.
Oliver L, Alvarez R, Diaz R, Valdés A, Colligan SH, Nemeth MJ, Twum DYF, Fernández A, Fernández-Medina O, Carlson LM, Yu H, Eng KH, Hensen ML, Rábade-Chediak ML, Fernández LE, Lee KP, Perez L, Muhitch JB, Mesa C, Abrams SI. Oliver L, et al. Among authors: perez l. J Immunother Cancer. 2022 Sep;10(9):e004710. doi: 10.1136/jitc-2022-004710. J Immunother Cancer. 2022. PMID: 36150744 Free PMC article. Clinical Trial.